Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 24.08.20 with a price of €111.76. With a performance of -2.83%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 11.008% | 11.008% | 19.967% | 39.932% |
| iShares Core DAX® | 0.388% | 0.145% | 10.959% | 58.440% |
| iShares Nasdaq 100 | 1.307% | -2.548% | -0.608% | 84.240% |
| iShares Nikkei 225® | -0.463% | 6.891% | 26.748% | 63.400% |
| iShares S&P 500 | 1.314% | -1.163% | -0.036% | 58.216% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


